VERUNasdaqPharmaceutical PreparationsFiscal year ends September 30
VERU INC.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.31+0.01 (+0.43%)
Close on Oct 19, 2026
- Market cap
- $53.25M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 1.0% | -60.8% | -89.7% | |
| Return on assets | 0.9% | -36.1% | -50.4% | |
| Current ratio | 4.87 | 1.83 | 2.43 | |
| Interest coverage | – | -3.2× | – | |
| Inventory turnover | 4.1× | 2.3× | – | |
| Capex to revenue | 0.0% | 0.2% | – | |
| Diluted shares | 3M | 7M | 15M |
Where the cash went
Fiscal 2021 to 2025, five years combined
VERU generated $202.82M from operations and spent $1.93M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$202.82M
Used
$1.93M
Capital expenditure$1.93M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-223.9%
×Asset turnover0.31×
×Equity multiplier2.12×
=Return on equity, FY2024-145.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -223.9% | 0.31× | 2.12× | -145.4% |
| FY2023 | -571.6% | 0.18× | 1.81× | -181.8% |
| FY2022 | -213.5% | 0.25× | 1.32× | -70.8% |
| FY2021 | 12.1% | 0.53× | 1.24× | 8.0% |
| FY2020 | -44.5% | 0.81× | 1.68× | -60.8% |
| FY2019 | -37.8% | 0.62× | 1.65× | -38.9% |
| FY2018 | -150.9% | 0.31× | 1.33× | -61.4% |
| FY2017 | -48.4% | 0.29× | 1.14× | -16.1% |
| FY2016 | 1.6% | 0.58× | 1.13× | 1.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$22.73M
- Cash generatingOperating cash flow above zero-$30.04M
- Return on assets improvedROA up on the prior year-75.6% → -37.6%
- Earnings backed by cashOperating cash flow above net income-$30.04M vs -$22.73M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.97 → 2.43
- No dilutionShare count did not rise13M → 15M
- Gross margin improvedGross margin up on the prior year34.67% → –
- More efficientAsset turnover rose0.34 → –